155 related articles for article (PubMed ID: 36963600)
1. Longitudinal Analysis of Ocular Manifestation and Interleukin During Intravitreal Treatment of Vitreoretinal Lymphoma With Methotrexate.
Gu J; Jiang T; Liu S; Chen X; Wang Z; Zhang P; Wang L; Jiang R; Huang X; Xu G; Chang Q
Am J Ophthalmol; 2023 Jul; 251():189-196. PubMed ID: 36963600
[TBL] [Abstract][Full Text] [Related]
2. A proposed protocol of intravitreal injection of methotrexate for treatment of primary vitreoretinal lymphoma.
Zhou N; Xu X; Liu Y; Wang Y; Wei W
Eye (Lond); 2022 Jul; 36(7):1448-1455. PubMed ID: 34211136
[TBL] [Abstract][Full Text] [Related]
3. Changes in choroidal vascular structure from vitreoretinal lymphoma and the intraocular cytokine level associated with clinical resolution after intravitreal methotrexate treatment.
Kim RY; Park JH; Kim M; Park YG; Cho SG; Park YH
PLoS One; 2021; 16(11):e0260469. PubMed ID: 34813633
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal observation of OCT imaging is a valuable tool to monitor primary vitreoretinal lymphoma treated with intravitreal injections of methotrexate.
Zhao H; Wang X; Mao Y; Peng X
BMC Ophthalmol; 2020 Jan; 20(1):10. PubMed ID: 31906917
[TBL] [Abstract][Full Text] [Related]
5. INTRAVITREAL MELPHALAN INJECTION AS A SECOND-LINE LOCAL THERAPY IN VITREORETINAL LYMPHOMA: Case Series.
Guneri Beser B; Demirci H
Retina; 2024 Feb; 44(2):353-359. PubMed ID: 37883576
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of intravitreal methotrexate for vitreo-retinal lymphoma - 20 years of experience.
Habot-Wilner Z; Frenkel S; Pe'er J
Br J Haematol; 2021 Jul; 194(1):92-100. PubMed ID: 33900619
[TBL] [Abstract][Full Text] [Related]
7. Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients.
Zhou X; Zhou X; Shi H; Lai J; Wang Q; Li Y; Chen K; Li Q; Zhou Q; Cao X; Chen B; Xiao J
BMC Ophthalmol; 2020 May; 20(1):189. PubMed ID: 32397978
[TBL] [Abstract][Full Text] [Related]
8. Aqueous Humor-Derived MYD88 L265P Mutation Analysis in Vitreoretinal Lymphoma: A Potential Less Invasive Method for Diagnosis and Treatment Response Assessment.
Demirci H; Rao RC; Elner VM; Demirci FY; Axenov L; Betz B; Behdad A; Brown N
Ophthalmol Retina; 2023 Feb; 7(2):189-195. PubMed ID: 35952929
[TBL] [Abstract][Full Text] [Related]
9. Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate.
Jiang T; Gu J; Liu S; Chang Q
BMC Ophthalmol; 2022 Sep; 22(1):375. PubMed ID: 36127675
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience.
Frenkel S; Hendler K; Siegal T; Shalom E; Pe'er J
Br J Ophthalmol; 2008 Mar; 92(3):383-8. PubMed ID: 18303160
[TBL] [Abstract][Full Text] [Related]
11. Serial changes in the aqueous IL-10 level after intravitreal methotrexate injection as an indicator of primary vitreoretinal lymphoma recurrence.
Park YG; Park WK; Kim RY; Kim M; Park YH
Sci Rep; 2020 Oct; 10(1):15992. PubMed ID: 33009434
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of combined intravitreal methotrexate and systemic high-dose methotrexate therapy in vitreoretinal lymphoma.
Cheng CL; Yeh PT; Fang WQ; Ma WL; Hou HA; Tsai CH; Lin CP; Tien HF
Cancer Med; 2023 Apr; 12(7):8102-8111. PubMed ID: 36602288
[TBL] [Abstract][Full Text] [Related]
13. Treatment of primary intraocular lymphoma with intravitreal methotrexate.
Sou R; Ohguro N; Maeda T; Saishin Y; Tano Y
Jpn J Ophthalmol; 2008; 52(3):167-174. PubMed ID: 18661266
[TBL] [Abstract][Full Text] [Related]
14. Vitreoretinal lymphoma: changing trends in diagnosis and local treatment modalities at a single institution.
Turaka K; Bryan JS; De Souza S; Gordon AJ; Kwong HM; Ziemianski MC; Reddy R; Sell CH
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):412-7. PubMed ID: 22995952
[TBL] [Abstract][Full Text] [Related]
15. Multimodal imaging characteristics in eyes with vitreoretinal lymphoma treated with intravitreal rituximab.
Rishi P; Maitra P; Das K; Rishi E; Manchegowda PT
Int Ophthalmol; 2021 Aug; 41(8):2711-2722. PubMed ID: 33834345
[TBL] [Abstract][Full Text] [Related]
16. Tumor Control and Visual Acuity Outcomes in Vitreoretinal Lymphoma with and without Sub-Retinal Pigment Epithelium Infiltration: Analysis of 125 Eyes of 70 Patients at a Single Ocular Oncology Center.
Dalvin LA; Lim LS; Ancona-Lezama D; Mazloumi M; Chang M; Mashayekhi A; Shields CL
Ophthalmol Retina; 2019 Nov; 3(11):998-1005. PubMed ID: 31358444
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes following intravitreal methotrexate for primary vitreoretinal lymphoma.
Anthony CL; Bavinger JC; Shantha JG; O'Keefe GD; Pearce WA; Voloschin A; Grossniklaus HE; Yeh S
Int J Retina Vitreous; 2021 Dec; 7(1):72. PubMed ID: 34863313
[TBL] [Abstract][Full Text] [Related]
18. Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma.
Hashida N; Nakai K; Saitoh N; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2014 Apr; 252(4):687-93. PubMed ID: 24549401
[TBL] [Abstract][Full Text] [Related]
19. USE OF A THRESHOLD OF INTERLEUKIN-10 AND IL-10/IL-6 RATIO IN OCULAR SAMPLES FOR THE SCREENING OF VITREORETINAL LYMPHOMA.
Pochat-Cotilloux C; Bienvenu J; Nguyen AM; Ohanessian R; Ghesquières H; Sève P; Garnier L; Kodjikian L
Retina; 2018 Apr; 38(4):773-781. PubMed ID: 29135797
[TBL] [Abstract][Full Text] [Related]
20. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement.
Smith JR; Rosenbaum JT; Wilson DJ; Doolittle ND; Siegal T; Neuwelt EA; Pe'er J
Ophthalmology; 2002 Sep; 109(9):1709-16. PubMed ID: 12208721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]